The Conference Board's Consumer Confidence Index tumbled to 81.9, a decline of 6.7 points and a reading well below the forecast for 89.

Traders were pricing in a better than 92% probability of a rate increase, as well as a more than 75% chance for another one in December.

Traders were pricing in a better than 92% probability of a rate increase, as well as a more than 75% chance for another one in December.

Traders were pricing in a better than 92% probability of a rate increase, as well as a more than 75% chance for another one in December.

Traders were pricing in a better than 92% probability of a rate increase, as well as a more than 75% chance for another one in December.

Traders were pricing in a better than 92% probability of a rate increase, as well as a more than 75% chance for another one in December.

Labatt and Molson beers and Fireball shots won’t disappear in the U.S. — here’s why

Nonfarm payrolls rose by just 29,000 in September, well below the 84,000 forecast, and the unemployment rate rose to 4.2%, the Bureau of Labor Statistics said.

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant re...

Bonava (OM:BONAV B) remains unprofitable, with losses having accelerated at an average annual rate of 53.9% over the past five years. However, forecasts project a sharp turnaround, with annual earning...

Bonava (OM:BONAV B) remains unprofitable, with losses having accelerated at an average annual rate of 53.9% over the past five years. However, forecasts project a sharp turnaround, with annual earning...

Bonava (OM:BONAV B) remains unprofitable, with losses having accelerated at an average annual rate of 53.9% over the past five years. However, forecasts project a sharp turnaround, with annual earning...